Lyme Disease Diagnostic Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Lyme Disease Diagnostic Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Lyme Disease Diagnostic Market is expected to register a CAGR of 5.5% during the forecast period (2022-2027).

The worldwide COVID-19 pandemic has eclipsed the attention of healthcare professionals, affecting all areas of health and diagnostics care. The crisis has had several indirect health effects as well. People with Lyme disease symptoms were asked to postpone their tests, as the coronavirus spread began to take over the world. Moreover, the common symptoms of Lyme and COVID-19 viruses often start with non-specific flu-like symptoms with fever, headache, and general achiness and fatigue, which made patients and medical experts more concerned about both infections in individuals. Thus, patients were suggested to diagnose with the available medical institutions helping to diagnose other diseases. Furthermore, rising incidences of new vector-borne diseases, growing government initiatives, and rising healthcare expenditure are some more factors that are fuelling the market growth.

The rise in prevalence of Lyme disease, favorable government towards healthcare facilities, and the emergence of new Lyme diagnostic tests are the main driving factors for this market. Moreover, the increasing number of cases of tick-borne diseases is also promoting the growth of the Lyme disease diagnostic market. For instance, in 2021, according to the Centre for Disease Control and Prevention number of cases of tick-borne diseases reported was 47,743, leading to the adoption of Lyme disease diagnostic tests. For another instance, in 2022 United States Fair Health Organization reported that Lyme disease has experienced notable growth in the United States over the past 15 years and, as a result, has become an illness of increasing national concern. The same source also quoted that in 2021, private insurance claim lines with Lyme disease diagnoses rose by 357 percent in rural areas and 65 percent in urban areas from the past decade. Although Lyme disease is treatable with antibiotics, some Lyme patients later develop conditions with long-term symptoms, such as fatigue, muscle, and joint pain, and cognitive issues. Such conditions have been linked to post-treatment Lyme disease syndrome, sometimes called chronic Lyme disease.

The growing government initiatives and preventive measures are another reason to drive this market. For instance, in 2022 an article titled, “New laws seek to boost funding of Lyme disease research” reported that New York officials have boosted funding for Lyme disease and tick-borne illnesses under a new law signed by Gov. Kathy Hochul. The measures, approved with bipartisan support, will create a voluntary tax check-off box to fund education, research, and prevention of this disease in the region. But despite the high instances of Lyme and tick-borne illnesses, the number of cases is believed to be much higher because of inaccurate diagnostic testing. It takes effect immediately Lawmakers have called for additional funding to research these illnesses, which they say have fallen behind federal and state levels. Thus, such a preventive government is driving its growth.

Thus, due to aforesaid mentioned reasons, the market is expected to show significant growth over the forecast period. However, lack of awareness regarding the disease is the reason which may slow down the growth of the market over the forecast period.

Key Market TrendsSerological​ Test Segment to Witness Significant Growth Over the Forecast Period in the Lyme Disease Diagnostic Market.

Serological tests are blood tests conducted to detect and measure the concentration of antibodies against bacteria, viruses, and any other foreign particle. Serological tests are widely used for the diagnosis of different types of bacterial, fungal, as well as viral infections. These tests have wide applications in diagnostic laboratories for the detection of infectious diseases, blood group typing, and diagnosis of autoimmune disorders.

The serological test is expected to dominate the segment as this test is highly preferable among all the tests owing to measures the antibodies in the late phase of the illness when both the nucleic acid test and polymerase chain reaction test are negative. These tests are very beneficial in terms of evaluating Lyme disease. Serological tests include ELISA, agglutination, precipitation, and western blot methods used to identify infectious diseases. Moreover, the rising prevalence of Lyme disease and growing demand for diagnostic tests among the targeted patient pool opt for this test and promote the Lyme disease diagnostic market. For instance, in 2021 an article titled “Recent Progress in Lyme Disease and Remaining Challenges” published in the journal Frontiers reported that Lyme disease (also known as Lyme borreliosis) is the most common vector-borne disease in the United States with an estimated 476,000 cases per year.

Recent technological advancements and growing demand for diagnostic tests among the targeted patient is driving this market segment. In June 2022, Adaptive Biotechnologies Corporation aimed to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease and announced the launch of T-Detect Lyme. The T-Detect test detects an immune response by leveraging the body’s unique T-cell response to disease-associated antigens. T-Detect Lyme identifies T cells activated by Borrelia burgdorferi, the bacterium that causes Lyme disease, to help diagnose early Lyme disease.

Thus, due to the above-mentioned aforesaid reasons, the market segment is expected to show significant market growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the global Lyme disease diagnostic market. This can be attributed to the increasing prevalence of tick-borne diseases and increasing initiatives by government and private institutes for diagnosing Lyme disease in this region. For instance, in 2021 according to the Centers for Disease Control and Prevention (CDC), around 300000 people were diagnosed with Lyme disease every year in North America. Furthermore, increasing healthcare expenditure and the presence of well-established healthcare infrastructure are also fuelling the growth of the overall regional market to a large extent.

Sever prominent key market players in the region have expanded their Lyme disease diagnostic portfolios for detecting germs that cause Lyme diseases. For instance, in 2022 T2 Biosystems created T2Lyme Panel Diagnostic technology for detecting germs that cause Lyme diseases. Thus, these technological advancements are propelling the North America Lyme disease diagnostic market ahead. Metabolic biomarkers and biosignatures are being identified and characterized for improved diagnosis. All these technologies contribute to advancing therapeutic development, thus again leading to the advancement of this market in the North American region.

Thus, due to the abovementioned reasons, the market is expected to show significant market growth in the North American region over the forecast period.

Competitive Landscape

The Lyme disease diagnostic market is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are in the market are Abbott, Bio-Rad Laboratories, Inc., Covance Inc., F. Hoffmann-La Roche AG, T2 Biosystems, Inc, and Oxford Immunotec USA, Inc..

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.